# To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

> **NCT06192849** · PHASE2 · RECRUITING · sponsor: **Juan LI, MD** · enrollment: 20 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- EGFR Exon 20 Insertion Mutation

## Interventions

- **DRUG:** Furmonertinib

## Key facts

- **NCT ID:** NCT06192849
- **Lead sponsor:** Juan LI, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-31
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-01-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06192849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06192849, "To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06192849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*